PORTLAND, Ore., Aug. 14 (UPI) -- Gleevec, nicknamed the "leukemia pill" and heralded last year for its dramatic effectiveness against chronic myelogenous leukemia, or CML, has demonstrated its powers against a second, previously hopeless cancer, an international team of researchers reports.
Advertisement